In Reply We thank Bergquist and colleagues for their interest in our article¹ on the association of aspirin use with biliary tract cancer (BTC) survival in the UK’s Clinical Practice Research Datalink (CPRD). We agree that the results cannot be the sole justification to incorporate aspirin therapy into the standard management of BTCs. For that, careful replication of the findings and, if possible, a randomized clinical trial are needed to provide further evidence. We also agree that the analysis has limitations that are typical with the use of electronic databases for observational research. We appreciate the opportunity to respond to these limitations beyond what was discussed in our article.

回复我们感谢 Bergquist 及其同事对我们在英国临床实践研究数据链 (CPRD) 中关于阿司匹林使用与胆道癌 (BTC) 存活率关联的文章^{1 的}关注。我们同意结果不能作为将阿司匹林治疗纳入 BTC 标准管理的唯一理由。为此，需要仔细复制研究结果，并在可能的情况下进行随机临床试验以提供进一步的证据。我们也同意该分析具有使用电子数据库进行观察性研究的典型局限性。我们很高兴有机会对我们文章中讨论的这些限制做出回应。